Why I would buy these healthcare shares in 2018

One of the best performing areas of the market this year has been the healthcare sector.

With just one trading day left before the end of 2017 trade, the S&P/ASX 200 Health Care (Index: ^AXHJ) (ASX: XHJ) is up almost 24% thanks partly to the strong performance of the CSL Limited (ASX: CSL) share price.

While I wouldn’t necessarily expect a gain of this magnitude next year, I believe there are a number of healthcare shares with the potential to beat the market.

Here are two to consider:

Volpara Health Technologies Limited (ASX: VHT)

This exciting digital health company focused on the early detection of breast cancer recently provided the market with a positive trading update. That update revealed that annual recurring revenue is at NZ$2.6 million as of December 15, representing 138% growth on the prior corresponding period. Further to this, management believes that it is on course to meet or exceed its 200% target for the full year. Growth of this level is hard to find and could make Volpara worth a closer look.

Zenitas Healthcare Ltd (ASX: ZNT)

I believe that this home care and health services company is well-positioned to grow strongly over the next few years thanks to the National Healthcare Reform. Changes have been made with the aim of pushing the burden of healthcare services from hospitals into primary care. Furthermore, Zenitas has opportunities to accelerate its growth through acquisitions thanks to the highly fractured industry it operates in.

Lastly, here are three more fast-growing shares that I think investors ought to consider buying in 2018.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of VOLPARA FPO NZ. The Motley Fool Australia has recommended Zenitas Healthcare Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.